Animal models of fibrotic lung disease.
Bethany B. Moore,William Lawson,William Lawson,Tim D. Oury,Thomas H. Sisson,Krishnan Raghavendran,Cory M. Hogaboam +6 more
Reads0
Chats0
TLDR
Each of the models reviewed in this report offers a powerful tool for studying some aspect of fibrotic lung disease and has a much better understanding of the fact that the aged lung has increased susceptibility to fibrosis.Abstract:
Interstitial lung fibrosis can develop as a consequence of occupational or medical exposure, as a result of genetic defects, and after trauma or acute lung injury leading to fibroproliferative acute respiratory distress syndrome, or it can develop in an idiopathic manner. The pathogenesis of each form of lung fibrosis remains poorly understood. They each result in a progressive loss of lung function with increasing dyspnea, and most forms ultimately result in mortality. To better understand the pathogenesis of lung fibrotic disorders, multiple animal models have been developed. This review summarizes the common and emerging models of lung fibrosis to highlight their usefulness in understanding the cell–cell and soluble mediator interactions that drive fibrotic responses. Recent advances have allowed for the development of models to study targeted injuries of Type II alveolar epithelial cells, fibroblastic autonomous effects, and targeted genetic defects. Repetitive dosing in some models has more closely mimicked the pathology of human fibrotic lung disease. We also have a much better understanding of the fact that the aged lung has increased susceptibility to fibrosis. Each of the models reviewed in this report offers a powerful tool for studying some aspect of fibrotic lung disease.read more
Citations
More filters
Journal ArticleDOI
Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis
Arun C. Habermann,Austin J. Gutierrez,Linh T. Bui,Stephanie L. Yahn,Nichelle I. Winters,Carla L. Calvi,Lance M. Peter,Mei-I Chung,Chase J. Taylor,Christopher S. Jetter,Latha Raju,Jamie Roberson,Guixiao Ding,Lori Wood,Jennifer M.S. Sucre,Bradley W. Richmond,Bradley W. Richmond,Ana P. Serezani,Wyatt J. McDonnell,Simon B. Mallal,Simon B. Mallal,Matthew J. Bacchetta,James E. Loyd,Ciara M. Shaver,Lorraine B. Ware,Ross M. Bremner,Rajat Walia,Timothy S. Blackwell,Timothy S. Blackwell,Timothy S. Blackwell,Nicholas E. Banovich,Jonathan A. Kropski,Jonathan A. Kropski,Jonathan A. Kropski +33 more
TL;DR: It is reported that a remarkable shift in epithelial cell phenotypes occurs in the peripheral lung in PF and several previously unrecognized epithelialcell phenotypes are identified, including a KRT5−/KRT17+ pathologic, ECM-producing epithel cell population that was highly enriched in PF lungs.
Journal ArticleDOI
The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease.
Gerald Burgstaller,Bettina Oehrle,Michael Gerckens,Eric S. White,Herbert B. Schiller,Oliver Eickelberg +5 more
TL;DR: This review summarises the available data about the structure and function of the pulmonary ECM, and highlights changes that occur in idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), asthma and lung cancer.
Journal ArticleDOI
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases.
Boris Hinz,David Lagares +1 more
TL;DR: Targeting myofibroblast apoptosis and reprogramming these cells to become scar-resolving cells are emerging as novel therapeutic strategies to reverse established fibrosis.
Journal ArticleDOI
An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis.
R. Gisli Jenkins,Bethany B. Moore,Rachel C. Chambers,Oliver Eickelberg,Melanie Königshoff,Martin Kolb,Geoffrey J. Laurent,Carmel B. Nanthakumar,Mitchell Alan Olman,Annie Pardo,Moises Selman,Dean Sheppard,Patricia J. Sime,Andrew M. Tager,Amanda L. Tatler,Victor J. Thannickal,Eric S. White +16 more
TL;DR: The consensus view is that use of the murine intratracheal bleomycin model in animals of both genders, using hydroxyproline measurements for collagen accumulation along with histologic assessments, is the best‐characterized animal model available for preclinical testing.
Journal ArticleDOI
Resolution of organ fibrosis
Joon Il Jun,Lester F. Lau +1 more
TL;DR: The present knowledge and gaps in the understanding of how matrix degradation is regulated and how myofibroblast cell fates can be manipulated are discussed, areas that may identify potential therapeutic approaches for fibrosis.
References
More filters
Journal ArticleDOI
Genomic Profile of Matrix and Vasculature Remodeling in TGF-α–Induced Pulmonary Fibrosis
William D. Hardie,Thomas R. Korfhagen,Maureen A. Sartor,Adrienne Prestridge,Mario Medvedovic,Timothy D. Le Cras,Machiko Ikegami,Scott C. Wesselkamper,Cynthia Davidson,Maggie Dietsch,William C. Nichols,Jeffrey A. Whitsett,George D. Leikauf +12 more
TL;DR: This paper showed that TGF-α expression in the respiratory epithelium of transgenic mice caused pulmonary fibrosis, cachexia, pulmonary hypertension, and altered lung function, when no longer induced, lung remodeling partially reversed and lung function and pulmonary hypertension normalized.
Journal ArticleDOI
Identification of Transforming Growth Factor β1-Driven Genetic Programs of Acute Lung Fibrosis
Anne-Marie Pulichino,I-Ming Wang,Alexandre Caron,James R. Mortimer,Anick Auger,Yves Boie,Jack A. Elias,Aileen Kartono,Lijing Xu,Joseph Menetski,Camil E. Sayegh +10 more
TL;DR: Using gene expression profiling in lungs, temporal activation of key genetic programs regulating cell movement and invasiveness, inflammation, organ remodeling, and fibrosis is demonstrated.
Journal ArticleDOI
A novel model for human interstitial lung disease: hapten-driven lung fibrosis in rodents.
Simon B. Roberts,Sarah E. M. Howie,William Wallace,Deborah Brown,D. Lamb,E. A. Ramage,Ken Donaldson +6 more
TL;DR: A novel model of chronic pulmonary fibrosis in rodents induced by a single intratracheal instillation of a well‐characterized fluorescent haptenic antigen, fluorescein isothiocyanate, which results in an acute inflammatory response involving a granulocytic infiltrate, which disappears over a week and is replaced by a chronic mononuclear infiltrate in which T lymphocytes predominate.
Journal ArticleDOI
Telomerase deficiency does not alter bleomycin-induced fibrosis in mice
Amber L. Degryse,Xiaochuan C. Xu,J. Luke Newman,Daphne B. Mitchell,Harikrishna Tanjore,Vasiliy V. Polosukhin,Brittany R. Jones,Frank B. McMahon,Linda A. Gleaves,John A. Phillips,Joy D. Cogan,Timothy S. Blackwell,William Lawson +12 more
TL;DR: Following bleomycin, TERT-deficient and TERC-def deficient mice developed an equivalent inflammatory response and similar lung fibrosis compared to controls, a pattern seen in both early (F1) and later (F6 TERT and F4 TERC) generations.
Journal ArticleDOI
Genetics in Pulmonary Fibrosis—Familial Cases Provide Clues to the Pathogenesis of Idiopathic Pulmonary Fibrosis
TL;DR: FIP families hold great promise in defining IPF pathogenesis, potentially suggesting targets for the development of future therapies and serving as a resource for identifying the current and future genetic links to disease.
Related Papers (5)
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management
Ganesh Raghu,Harold R. Collard,Jim J. Egan,Fernando J. Martinez,Juergen Behr,Kevin K. Brown,Thomas V. Colby,Jean-François Cordier,Kevin R. Flaherty,Joseph A. Lasky,David A. Lynch,Jay H. Ryu,Jeffrey J. Swigris,Athol U. Wells,Julio Ancochea,Demosthenes Bouros,Carlos Roberto Ribeiro de Carvalho,Ulrich Costabel,Masahito Ebina,David M. Hansell,Takeshi Johkoh,Dong Soon Kim,Talmadge E. King,Yasuhiro Kondoh,Jeffrey L. Myers,Nestor L. Müller,Andrew G. Nicholson,Luca Richeldi,Moisés Selman,Rosalind F. Dudden,Barbara S. Griss,Shandra Protzko,Holger J. Schünemann +32 more
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi,Roland M. du Bois,Ganesh Raghu,Arata Azuma,Kevin K. Brown,Ulrich Costabel,Vincent Cottin,Kevin R. Flaherty,David M. Hansell,Yoshikazu Inoue,Dong Soon Kim,Martin Kolb,Andrew G. Nicholson,Paul W. Noble,Moisés Selman,Hiroyuki Taniguchi,Michèle Brun,Florence Le Maulf,Mannaig Girard,Susanne Stowasser,Rozsa Schlenker-Herceg,Bernd Disse,Harold R. Collard +22 more